HIND
Vyome Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.22
−0.45%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 129.7K | 319.7K | 8.0M | 8.7M | 11.2M |
| Cost of Revenue | 69.4K | 112.9K | 2.9M | 3.1M | 4.4M |
| Gross Profit | 60.3K | 206.8K | 5.1M | 5.5M | 6.8M |
| Operating Expenses | |||||
| R&D Expense | 1.6M | 588.3K | 1.8M | 2.3M | 2.5M |
| SG&A Expense | 2.7M | 2.4M | 9.9M | 17.9M | 31.3M |
| General & Admin Expense | 364.9K | — | 6.9M | — | — |
| Selling & Marketing Expense | — | — | 3.0M | — | — |
| Other Expenses | 2.6K | — | 1.1M | — | — |
| Total Operating Expenses | 4.3M | 3.0M | 12.8M | 20.2M | 33.9M |
| Cost and Expenses | 4.3M | 3.1M | 15.7M | 23.3M | 38.3M |
| Operating Income (EBIT) | (4.2M) | (2.7M) | (7.7M) | (14.6M) | (27.1M) |
| Non-Operating | |||||
| Interest Income | 146.2K | — | 14.0K | 26.0K | — |
| Interest Expense | 41.7K | 146.6K | — | — | 113.0K |
| Net Interest Income | 104.5K | (146.6K) | 14.0K | 26.0K | (113.0K) |
| Other Non-Op Income/Expense | (7.4M) | (7.7M) | 637.0K | 3.3M | (19.5M) |
| Non-Operating Income (excl Interest) | 7.3M | 7.6M | (1.1M) | (3.3M) | 19.4M |
| EBT (Pre-Tax Income) | (11.6M) | (10.5M) | (7.1M) | (11.3M) | (46.6M) |
| Income Tax Expense | — | — | 39.0K | 52.0K | (380.0K) |
| Bottom Line | |||||
| Net Income | (11.3M) | (10.3M) | (7.1M) | (11.4M) | (46.2M) |
| Earnings from Cont. Ops | (11.6M) | (10.5M) | (7.1M) | (11.4M) | (46.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (11.3M) | (10.3M) | (7.1M) | (11.4M) | (46.2M) |
| Per Share | |||||
| Basic EPS | ($29.90) | ($4.75) | ($345.74) | ($2,771.94) | ($157,897.00) |
| Diluted EPS | ($29.90) | ($4.75) | ($345.74) | ($2,771.94) | ($157,897.00) |
| Revenue Per Share | $0.02 | $0.15 | $388.23 | $2,112.98 | $38,403.36 |
| Shares | |||||
| Basic Shares Outstanding | 7.0M | 2.2M | 20622 | 4107 | 293 |
| Diluted Shares Outstanding | 7.0M | 2.2M | 20622 | 4107 | 293 |
| Profitability Metrics | |||||
| EBITDA | (11.5M) | (10.3M) | (6.6M) | (11.2M) | (44.3M) |
| D&A | 10.7K | 12.0K | 22.0K | 154.0K | 2.2M |
| EBIT | (11.5M) | (10.3M) | (6.7M) | (11.3M) | (46.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026